6[1]Rai JL.Recommendations for the management of special populations:renal disease in diabetes[J].Am J Hypertens,2003,16(11Pt 2):46-49.
7[2]胡仁明.糖尿病肾病的相关研究[N].中国医学论坛报,2005,8:11.
8[4]Kislinger T,Fu C,Huber B,et al.N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression[J].J Biol Chem,1999,274(44):31740-31749.
9[5]Beisswenger PJ,Makita Z,Curphey TJ,et al.Formation of immunochemical advanced glycosylation end-products precedes and correlates with early manifestations of renal and retinal disease in diabetes[J].Diabetes,1995,44(7):824-829.
10[6]Doi T,Vlassara H,Kirstein M,et al.Receptor-specific increase in extracelluar matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platederived growth factor[J].Proc Natl Acad Sci USA,1992,89(7):2873.
3Garber A J, Abrahamson M J, Barzilay JI, et al. American Association of Clinical Endocrinologists'comprehensive diabetes management algo- rithm 2013 consensus statement-executive summary [ J ]. Endocr Pract ,2013,19 ( 3 ) :536-557.
4Martha S, Devarakonda KR, Anreddy RN, et al. Effect of aspirin treatment in streptozotocin-induced type 2 diabetic rats [ J ]. Methods Find Exp Clin Pharmacol,2009 ,31 (5) :331-335.
5James PA, Oparit S, Carter BL, et al. 2014 evidence-based guide- line for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [J]. JAMA,2014,311(5) :507-520.
7De Zeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment[J]. J Hum Hy- pertens, 1997,11 Suppl 2 : S37-S42.
8Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagula- tion with warfarin-fourth edition [ J ]. Br J Haematol, 2011 , 154 ( 3 ) : 311-324.
9Pan Y, Guo LL, Jin HM. Low-protein diet for diabetic nephropathy : a meta-analysis of randomized controlled trials [ J ]. Am J Clin Nutr, 2008,88 ( 3 ) :660-666.
